[go: up one dir, main page]

HK1204966A1 - Combination of muscarinic receptor antagonists and beta- 3 adrenoceptor agonists for treating overactive bladder - Google Patents

Combination of muscarinic receptor antagonists and beta- 3 adrenoceptor agonists for treating overactive bladder Download PDF

Info

Publication number
HK1204966A1
HK1204966A1 HK15105751.1A HK15105751A HK1204966A1 HK 1204966 A1 HK1204966 A1 HK 1204966A1 HK 15105751 A HK15105751 A HK 15105751A HK 1204966 A1 HK1204966 A1 HK 1204966A1
Authority
HK
Hong Kong
Prior art keywords
beta
overactive bladder
combination
muscarinic receptor
receptor antagonists
Prior art date
Application number
HK15105751.1A
Other languages
English (en)
Chinese (zh)
Inventor
Stephen Caltabiano
Eliot Ohlstein
Stewart Mccallum
Original Assignee
Velicept Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Velicept Therapeutics, Inc. filed Critical Velicept Therapeutics, Inc.
Publication of HK1204966A1 publication Critical patent/HK1204966A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK15105751.1A 2012-02-09 2013-02-08 Combination of muscarinic receptor antagonists and beta- 3 adrenoceptor agonists for treating overactive bladder HK1204966A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261596893P 2012-02-09 2012-02-09
US201261596893P 2012-02-09
PCT/US2013/025285 WO2013119910A1 (fr) 2012-02-09 2013-02-08 Combinaison d'antagonistes des récepteurs muscariniques et d'agonistes de l'adrénorécepteur bêta -3 pour le traitement de la vessie hyperactive

Publications (1)

Publication Number Publication Date
HK1204966A1 true HK1204966A1 (en) 2015-12-11

Family

ID=48948043

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15105751.1A HK1204966A1 (en) 2012-02-09 2013-02-08 Combination of muscarinic receptor antagonists and beta- 3 adrenoceptor agonists for treating overactive bladder

Country Status (13)

Country Link
EP (1) EP2811989A1 (fr)
JP (1) JP2015509931A (fr)
KR (1) KR20150020160A (fr)
CN (1) CN104684549A (fr)
AR (1) AR089957A1 (fr)
AU (1) AU2013216864A1 (fr)
CA (1) CA2864173A1 (fr)
HK (1) HK1204966A1 (fr)
IL (1) IL234033A0 (fr)
PH (1) PH12014501814A1 (fr)
SG (1) SG11201404776PA (fr)
TW (1) TW201338772A (fr)
WO (1) WO2013119910A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9522129B2 (en) 2010-08-03 2016-12-20 Velicept Therapeutics, Inc. Pharmaceutical Combination
US9907767B2 (en) 2010-08-03 2018-03-06 Velicept Therapeutics, Inc. Pharmaceutical compositions and the treatment of overactive bladder
EP3226849A4 (fr) 2014-12-03 2018-05-09 Velicept Therapeutics, Inc. Compositions et procédés d'utilisation du solabégron à libération modifiée pour traiter des symptômes du bas appareil urinaire
FI3365321T3 (fi) 2015-10-23 2024-01-02 B3Ar Therapeutics Inc Solabegron-Zwitterioni ja sen käyttöjä
KR101868438B1 (ko) 2017-04-13 2018-06-20 (주) 성운파마코피아 아미드 유도체의 제조방법

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL267508A (fr) 1960-07-26
US5677346A (en) 1995-01-31 1997-10-14 Sepracor, Inc. Treating urinary incontinence using (S)-desethyloxybutynin
US6123961A (en) 1996-09-25 2000-09-26 Bridge Pharma, Inc. Treating urinary incontinence with (R)-desethyloxybutynin and (R)-oxybutynin
GB9812709D0 (en) 1998-06-13 1998-08-12 Glaxo Group Ltd Chemical compounds
GB9929297D0 (en) 1999-12-11 2000-02-02 Glaxo Group Ltd Process
GB0102407D0 (en) 2001-01-31 2001-03-14 Glaxo Group Ltd Process
TWI295669B (en) * 2002-10-30 2008-04-11 Theravance Inc Substituted 4-amino-1-(pyridylmethyl) piperidine and related compounds
EP1424079A1 (fr) * 2002-11-27 2004-06-02 Boehringer Ingelheim International GmbH Combinaison d'un agoniste du beta-3-récepteur et d'un inhibiteur de recaptage de sérotonine et/ou norépinéphrine
WO2008121268A1 (fr) * 2007-03-29 2008-10-09 Merck & Co., Inc. Polythérapie pour le traitement de troubles urinaires du bas appareil
PE20091825A1 (es) * 2008-04-04 2009-12-04 Merck & Co Inc Hidroximetil pirrolidinas como agonistas del receptor adrenergico beta 3
US8354403B2 (en) 2009-08-27 2013-01-15 Merck Sharp & Dohme Corp. Pyrrolidine derived beta 3 adrenergic receptor agonists
IN2012DN02782A (fr) * 2009-10-07 2015-09-18 Merck Sharp & Dohme

Also Published As

Publication number Publication date
AR089957A1 (es) 2014-10-01
AU2013216864A1 (en) 2014-09-11
CA2864173A1 (fr) 2013-08-15
SG11201404776PA (en) 2014-09-26
KR20150020160A (ko) 2015-02-25
CN104684549A (zh) 2015-06-03
JP2015509931A (ja) 2015-04-02
WO2013119910A1 (fr) 2013-08-15
TW201338772A (zh) 2013-10-01
PH12014501814A1 (en) 2014-11-24
IL234033A0 (en) 2014-09-30
EP2811989A1 (fr) 2014-12-17

Similar Documents

Publication Publication Date Title
PH12013500221A1 (en) Combinations of beta - 3 adrenergic receptor agonists and muscarinic receptor antagonists for treating overactive bladder
PH12013502551A1 (en) Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
TN2015000244A1 (en) Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
WO2016066634A3 (fr) Utilisation d'antagonistes du ccr5 en monothérapie ou en polythérapie pour le traitement du cancer
PH12014501814A1 (en) Combination of muscarinic receptor antagonists and beta-3 adrenoceptor agonists for treating overactive bladder
IL253922B (en) Compounds with muscarinic receptor antagonist and adrenergic receptor agonist activity in cell 2
MX2016001030A (es) Métodos y composiciones que comprenden desmopresina en combinación con un agonista del receptor beta 3-adrenérgico.
IL242748B (en) nmdar agonist for use in the treatment of glutamatergic receptor dysfunction from an autoimmune phenomenon
WO2011097336A3 (fr) Agonistes hautement sélectifs du récepteur 5-ht(2c) ayant une activité antagoniste au niveau du récepteur 5-ht(2b)
HK1185270A (en) Combinations of beta - 3 adrenergic receptor agonists and muscarinic receptor antagonists for treating overactive bladder
HK1168542A (en) Compositions comprising transnorsertraline and serotonin receptor 1a agonists/antagonists and uses thereof
TN2013000429A1 (en) Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity